Tramadol and O-Desmethyl Tramadol Clearance Maturation and Disposition in Humans: A Pooled Pharmacokinetic Study

Clinical Pharmacokinetics

Volumn 54, Issue 2, 2015, Pages 167-178

  Allegaert, Karel ^a   Holford, Nick ^b   Anderson, Brian J ^b   Holford, Sam ^b   Stuber, Frank ^c   Rochette, Alain ^d   Trocóniz, Iñaki F ^e   Beier, Horst ^f   de Hoon, Jan N ^a   Pedersen, Rasmus S ^g   Stamer, Ulrike ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF BERN   (Switzerland)

^d LAPEYRONIE HOSPITAL   (France)

^e UNIVERSITY OF NAVARRA   (Spain)

^f GRÜNENTHAL GMBH   (Germany)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; O DESMETHYL TRAMADOL; TRAMADOL; UNCLASSIFIED DRUG; ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; O-DEMETHYLTRAMADOL;

ADULT; ARTICLE; CHILD; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; FEMALE; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; HUMAN; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHENOTYPE; POSTMENOPAUSE; PREMATURITY; PRIORITY JOURNAL; SIGMOID; ADOLESCENT; AGED; AGED, 80 AND OVER; ANALOGS AND DERIVATIVES; CHILD, PRESCHOOL; GENETICS; GENOTYPE; HUMANS; INFANT; METABOLISM; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; TRAMADOL; YOUNG ADULT;

EID: 84940102047     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0191-9     Document Type: Article

References (42)

1. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923.
2. Reeves RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today. 2008;44(11):827–36.
3. Ardakani YH, Rouini MR. Pharmacokinetics of tramadol and its three main metabolites in healthy male and female volunteers. Biopharm Drug Dispos. 2007;28(9):527–34.
4. Gong L, Stamer UM, Tzvetkov MV, et al. PharmGKB summary: tramadol pathway. Pharmacogenet Genomics. 2014;24(7):374–80.
5. Allegaert K, Anderson BJ, Verbesselt R, et al. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. Br J Anaesth. 2005;95(2):231–9.
6. Allegaert K, van den Anker JN, de Hoon JN, et al. Covariates of tramadol disposition in the first months of life. Br J Anaesth. 2008;100(4):525–32.
7. Pedersen RS, Damkier P, Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol. 2006;62(7):513–21.
8. Stamer UM, Lehnen K, Höthker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003;105(1–2):231–8.
9. Murthy BV, Pandya KS, Booker PD, et al. Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration. Br J Anaesth. 2000;84(3):346–9.
10. Garrido MJ, Habre W, Rombout F, et al. Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. Pharm Res. 2006;23(9):2014–23.
11. Bressolle F, Rochette A, Khier S, et al. Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children. Br J Anaesth. 2009;102(3):390–9.
12. Lintz W, Barth H, Osterloh G, et al. Bioavailability of enteral tramadol formulations. 1st communication: capsules. Arzneimittelforschung. 1986;36(8):1278–83.
13. Lintz W, Barth H, Becker R, et al. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. Arzneimittelforschung. 1998;48(5):436–45.
14. Lintz W, Barth H, Osterloh G, et al. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd communication: suppositories. Arzneimittelforschung. 1998;48(9):889–99.
15. Lintz W, Beier H, Gerloff J. Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. Int J Clin Pharmacol Ther. 1999;37(4):175–83.
16. Lintz W, Becker R, Gerloff J, et al. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). Arzneimittelforschung. 2000;50(2):99–108.
17. Stamer UM, Musshoff F, Kobilay M, et al. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther. 2007;82(1):41–7.
18. Abdel-Rahman SM, Leeder JS, Wilson JT, et al. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol. 2002;42(1):24–9.
19. Blake MJ, Gaedigk A, Pearce RE, et al. Ontogeny of dextromethorphan O- and i-demethylation in the first year of life. Clin Pharmacol Ther. 2007;81(4):510–6.
20. Becker R, Lintz W. Determination of tramadol in human serum by capillary gas chromatography with nitrogen-selective detection. J Chromatogr. 1986;377:213–20.
21. Gan SH, Ismail R. Validation of a high-performance liquid chromatography method for tramadol and O-desmethyltramadol in human plasma using solid-phase extraction. J Chromatogr B. 2001;759(2):325–35.
22. Nobilis M, Kopecky J, Kvetina J, et al. High-performance liquid chromatographic determination of tramadol and its O-desmethylated metabolite in blood plasma: application to a bioequivalence study in humans. J Chromatogr A. 2002;949(1–2):11–22.
23. KuKanich B, Papich MG. Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. J Vet Pharmacol Ther. 2004;27(4):239–46.
24. Giorgi M, Del Carlo S, Saccomanni G, et al. Pharmacokinetics of tramadol and its major metabolites following rectal and intravenous administration in dogs. N Z Vet J. 2009;57(3):146–52.
25. Giorgi M, Soldani G, Manera C, et al. Pharmacokinetics of tramadol and its metabolites M1, M2 and M4 in horses following intravenous, immediate release (fasted/fed) and sustained release single dose administration. J Equine Vet Sci. 2007;27(11):481–8.
26. Holford S, Allegaert K, Anderson BJ, et al. Parent-metabolite pharmacokinetic models for tramadol: tests of assumptions and predictions. J Pharmacol Clin Toxicol. 2014;2(1):1023.
27. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59(1):19–29.
28. Holford NH. The visual predictive check: superiority to standard diagnostic (Rorschach) plots (http://www.page-meeting.org/?abstract=972). PAGE 2005;14:972.
29. Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.
30. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32.
31. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276(5309):122.
32. Tod M, Lokiec F, Bidault R, et al. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother. 2001;45(1):150–7.
33. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr. 2006;165(11):741–6.
34. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47(4):231–43.
35. Karlsson MO, Jonsson NE, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26(2):207–46.
36. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67–76.
37. Allegaert K, Rochette A, Veyckemans F. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Paediatr Anaesth. 2011;21(3):266–73.
38. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36.
39. Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol. 1990;39(6):533–7.
40. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60(2):284–95.
41. Caraco Y. Genes and the response to drugs. N Engl J Med. 2004;351(27):2867–9.
42. Stamer UM, Stüber F, Muders T, et al. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg. 2008;107(3):926–9.